Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 2
1953 9
1954 6
1956 3
1957 7
1958 5
1959 3
1962 1
1963 2
1964 3
1965 21
1966 26
1967 42
1968 51
1969 29
1970 50
1971 44
1972 73
1973 46
1974 63
1975 38
1976 32
1977 35
1978 36
1979 38
1980 43
1981 42
1982 33
1983 32
1984 40
1985 42
1986 58
1987 31
1988 55
1989 54
1990 49
1991 39
1992 39
1993 69
1994 58
1995 57
1996 57
1997 55
1998 60
1999 56
2000 52
2001 42
2002 55
2003 61
2004 68
2005 59
2006 116
2007 95
2008 95
2009 76
2010 104
2011 106
2012 99
2013 129
2014 119
2015 129
2016 102
2017 123
2018 93
2019 105
2020 94
2021 110
2022 126
2023 111
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

3,706 results

Results by year

Filters applied: . Clear all
Page 1
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Qi Y, Chan ML, Mould DR, Larimore K, Fisheleva E, Cherukuri A, Day J, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WR, Bober MB, Henshaw J. Qi Y, et al. Clin Pharmacokinet. 2024 May;63(5):707-719. doi: 10.1007/s40262-024-01371-6. Epub 2024 Apr 23. Clin Pharmacokinet. 2024. PMID: 38649657 Free PMC article.
BACKGROUND AND OBJECTIVE: Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short stature, that has been shown to be well tolerated and effective in increasing linear growth. ...Simulated exposure was compared wit …
BACKGROUND AND OBJECTIVE: Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short
Editorial: Short stature: beyond growth hormone.
Plachy L, Deodati A, Tornese G. Plachy L, et al. Front Endocrinol (Lausanne). 2024 Mar 28;15:1403112. doi: 10.3389/fendo.2024.1403112. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38606084 Free PMC article. No abstract available.
A Clinical Trial of High Dose Growth Hormone in a Patient with a Dominant Negative Growth Hormone Receptor Mutation.
Merchant N, Houchin L, Boucher K, Dauber A. Merchant N, et al. J Clin Endocrinol Metab. 2024 Apr 10:dgae244. doi: 10.1210/clinem/dgae244. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 38597155
CONTEXT: Rare patients with short stature and growth hormone (GH) resistance have dominant-negative variants in the GH receptor. ...PATIENT: Patient has a heterozygous variant in GH receptor resulting in elevated levels of GH binding protein manifesting as GH resist …
CONTEXT: Rare patients with short stature and growth hormone (GH) resistance have dominant-negative variants in the GH recepto …
Case report: Long term response to growth hormone in a child with Silver-Russell syndrome-like phenotype due to a novel paternally inherited IGF2 variant.
Ventresca S, Lepri FR, Criscuolo S, Bottaro G, Novelli A, Loche S, Cappa M. Ventresca S, et al. Front Endocrinol (Lausanne). 2024 Mar 26;15:1364234. doi: 10.3389/fendo.2024.1364234. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38596219 Free PMC article.
The most common features are intrauterine growth retardation (IUGR), poor postnatal development, macrocephaly, triangular face, prominent forehead, body asymmetry, and feeding problems. The diagnosis of SRS is based on a combination of clinical features. Up to 60% of SRS p …
The most common features are intrauterine growth retardation (IUGR), poor postnatal development, macrocephaly, triangular face, prominent fo …
[Discontinuation of tyrosine kinase inhibitors before epiphyseal closure leading to improved short stature in pediatric chronic myelogenous leukemia].
Fukui W, Ogura T, Azumi S, Ogata H, Kawaguchi K, Takachi T, Horikoshi Y, Uematsu A, Shimada H, Watanabe K. Fukui W, et al. Rinsho Ketsueki. 2024;65(3):175-179. doi: 10.11406/rinketsu.65.175. Rinsho Ketsueki. 2024. PMID: 38569862 Japanese.
The patient achieved molecular remission but became markedly short in stature, measuring 129.3 cm (height standard deviation score [SDS] -3.3) at the age of 12. ...Growth suppression by TKIs is a problem in the management of pediatric CML. This case illustrates how …
The patient achieved molecular remission but became markedly short in stature, measuring 129.3 cm (height standard deviation s …
[Management of transition growth hormone deficiency].
Cheng SQ. Cheng SQ. Zhongguo Dang Dai Er Ke Za Zhi. 2024 Mar 15;26(3):224-229. doi: 10.7499/j.issn.1008-8830.2309173. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 38557372 Free PMC article. Chinese.
With an increasing understanding of growth hormone deficiency, there has been a growing emphasis on the management of transition growth hormone deficiency (TGHD) in clinical practice. The inadequate diagnosis and treatment of TGHD have been a major clinical concern, …
With an increasing understanding of growth hormone deficiency, there has been a growing emphasis on the management of transition growth horm …
3,706 results